Thank you for visiting, don't forget to subscribe by following here if you enjoy our content. We use follow.it to give you maximum control over your news.
Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare sector payments spanning seven years.
The maker of weight-loss drug Wegovy was found to have misreported, under-reported, or completely omitted funding disbursed to pharmacy firms, obesity charities, training providers, professional bodies, and patient groups. The watchdog identified 48 breaches of industry code, highlighting serious compliance failures that occurred whilst the company was already under audit scrutiny.
Research conducted by academics at Bath and Lund universities revealed that even after Novo Nordisk’s internal review and claimed rectification, the company failed to accurately record payments totalling £635,000 to 30 organisations. These undisclosed transactions included a substantial £183,000 in funding to a weight-loss-coaching company partnering with pharmacies and the NHS.
The PMCPA’s ruling emphasises that these actions have “brought discredit upon, and reduced confidence in, the pharmaceutical industry.” The company had previously admitted to omitting over 500 transactions worth £7.8m between 2020 and 2022, leading to what the watchdog described as “fundamental governance failures.”
Industry experts are now calling for a comprehensive overhaul of pharmaceutical spending monitoring systems in Britain. Critics advocate for a government-run, centralised database with stringent enforcement mechanisms and penalties for non-compliance, moving beyond the current voluntary Disclosure UK scheme.
Novo Nordisk responded by stating their dedication to transparent and ethical working practices, acknowledging the seriousness of these historical transfer disclosures. The company maintains its commitment to adhering to industry codes and upholding ethical standards, though this latest controversy adds to growing scrutiny over their promotional tactics for weight-loss medications.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.